al-Shammaa HAH, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol 2008; 14(8): 1159-1166 [PMID: 18300340 DOI: 10.3748/wjg.14.1159]
Corresponding Author of This Article
Yan Li, MD, PhD, Department of Oncology, Zhongnan Hospital of Wuhan University, Cancer Center of Wuhan University, and Hubei Cancer Clinical Study Center, No 169 Donghu Road, Wuchang District, Wuhan 430071, Hubei Province, China. liyansd2@163.com
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 28, 2008; 14(8): 1159-1166 Published online Feb 28, 2008. doi: 10.3748/wjg.14.1159
Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis
Hassan Alaa Hammed al-Shammaa, Yan Li, Yutaka Yonemura
Hassan Alaa Hammed al-Shammaa, Yan Li, Department of Oncology, Zhongnan Hospital of Wuhan University, Cancer Center of Wuhan University, and Hubei Cancer Clinical Study Center, No 169 Donghu Road, Wuchang District, Wuhan 430071, Hubei Province, China
Yutaka Yonemura, Peritoneal Carcinomatosis Program, Shizuoka Cancer Center, Mishima, Japan
Correspondence to: Yan Li, MD, PhD, Department of Oncology, Zhongnan Hospital of Wuhan University, Cancer Center of Wuhan University, and Hubei Cancer Clinical Study Center, No 169 Donghu Road, Wuchang District, Wuhan 430071, Hubei Province, China. liyansd2@163.com
Telephone: +86-27-62337478
Fax: +86-27-67812892
Received: August 20, 2007 Revised: December 8, 2007 Published online: February 28, 2008
Abstract
This article is to offer a concise review on the use of cytoreductive surgery (CRS) plus intraperitoneal hyperthermic chemotherapy (IPHC) for the treatment of peritoneal carcinomatosis (PC). Traditionally, PC was treated with systemic chemotherapy alone with very poor response and a median survival of less than 6 mo. With the establishment of several phase II studies, a new trend has been developed toward the use of CRS plus IPHC as a standard method for treating selected patients with PC, in whom sufficient cytoreduction could be achieved. In spite of the need for more high quality phase III studies, there is now a consensus among many surgical oncology experts throughout the world about the use of this new treatment strategy as standard care for colorectal cancer patients with PC. This review summarizes the current status and possible progress in future.
